

### Rentokil Initial plc

Rentokil Initial plc (the 'Company') has been informed that on 17 September 2024 Andy Ransom, a Person Discharging Managerial Responsibility, acquired 4,386 ordinary shares of 1 pence in the Company as a result of his participation in the Company's Dividend Reinvestment Plan (DRIP). The shares were purchased at £3.793985 per share.

The notification set out below is provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

Rachel Canham  
Group General Counsel & Company Secretary  
+44 (0)1293 858 000

1	Details of the person discharging managerial responsibilities / person closely associated						
a)	Name	Andy Ransom					
2	Reason for the notification						
a)	Position/status	Chief Executive					
b)	Initial notification /Amendment	Initial notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Rentokil Initial plc					
b)	LEI	549300VN4WV/7Z6T14K68					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument	Ordinary shares of 1p each					
	Identification code	ISIN: GB00B082RF11					
b)	Nature of the transaction	Acquisition of shares through the Company's Dividend Reinvestment Plan (DRIP).					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£3.793985</td><td>4,386</td></tr></table>		Price(s)	Volume(s)	£3.793985	4,386
Price(s)	Volume(s)						
£3.793985	4,386						
d)	Aggregated information						
	- Aggregated volume	4,386					
	- Total price	£16,640.42					
e)	Date of the transaction	2024-09-17					
f)	Place of the transaction	London Stock Exchange (XLON)					

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHGRGDCC'BBDGSC